Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory
Iwa mimọ giga, iṣelọpọ Iṣowo
Olaparib ati Awọn agbedemeji ti o jọmọ:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoic acid CAS 763114-26-7
1- (Cyclopropylcarbonyl) piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Orukọ Kemikali | Olaparib |
| Awọn itumọ ọrọ sisọ | AZD-2281;KU0059436;Lynparza;4- (3- (4- (cyclopropanecarbonyl)) piperazine-1-carbonyl) -4-fluorobenzyl) phthalazin-1 (2H) -ọkan;1- (Cyclopropylcarbonyl) -4- [5-[(3,4-dihydro-4-oxo-1-phthalazinyl) Methyl]-2-fluorobenzoyl] piperazin |
| Nọmba CAS | 763113-22-0 |
| NỌMBA CAT | RF-API103 |
| Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn ọgọọgọrun Kilogram |
| Fọọmu Molecular | C24H23FN4O3 |
| Òṣuwọn Molikula | 434.46 |
| Solubility | Tiotuka ni DMSO |
| Brand | Ruifu Kemikali |
| Nkan | Awọn pato |
| Ifarahan | Funfun to Pa-White Powder |
| Idanimọ nipasẹ 1H NMR | Ni ibamu pẹlu eto naa |
| LC-MS | Ni ibamu pẹlu eto naa |
| Mimọ / Analysis Ọna | ≥99.0% (nipasẹ LC-MS) |
| Ọrinrin (KF) | ≤0.50% |
| Aimọ Kanṣoṣo | ≤0.50% |
| Lapapọ Awọn Aimọ | ≤1.0% |
| Awọn irin Heavy (gẹgẹbi Pb) | ≤20ppm |
| Igbeyewo Standard | Standard Enterprise |
| Lilo | API;Oludaniloju PARP |
Package: Igo, apo apamọwọ Aluminiomu, Ilu paali, 25kg / Drum, tabi gẹgẹbi ibeere alabara.
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin.
Olaparib (CAS: 763113-22-0), agbara ti o ga julọ ati yiyan PARP-inhibitor.Ni Oṣu Kejila ọjọ 19, Ọdun 2014, FDA fọwọsi aramada egboogi-akàn oogun Olaparib (Lynparza) fun monotherapy si awọn alaisan ti o ni ilọsiwaju ti akàn ọjẹ ti o ti gba o kere ju awọn iyipo 3 ti kimoterapi tabi awọn alaisan ti a fura si awọn iyipada BRCA.Ni akoko kanna, FDA fọwọsi titobi ati iyasọtọ ti awọn ohun elo iwadii fun wiwa awọn iyipada ninu BRCA1 ati BRCA2, BRACAnalysis CDx.Olaparib jẹ awọn oogun inhibitor PARP akọkọ eyiti FDA fọwọsi.Ni Kínní 2, 2015, European Union Food and Drug Administration (EMA) tun fọwọsi Olaparib lati wọ ọja ni awọn orilẹ-ede 28 ti European Union pẹlu Iceland, Liechtenstein ati Norway.Ṣugbọn awọn itọkasi ti EMA ati FDA fọwọsi jẹ iyatọ diẹ;ogbologbo jẹ fun awọn ọran jiini jiini BRCA, ati tun fun itọju itọju fun awọn alaisan ti o ni ilọsiwaju ti o ti ni ilọsiwaju epithelial ovarian akàn ti o ti gba awọn oogun chemotherapy ti o ni Platinum tẹlẹ ati ifihan esi ati koko-ọrọ si isọdọtun.
